KRAS Inhibitors- Yes But What Next? Direct targeting of KRAS- Vaccines, Adoptive T Cell Therapy and Beyond

Kirsten rat sarcoma viral oncogene homolog (KRAS) is a proto-oncogene of the RAS-MAPK pathway. KRAS mutations are present in a variety of malignancies including lung, colorectal, and pancreatic cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations [1]. The KRAS protein is a GTPase that transmits intracellular signals upon binding to GTP [2 –3]. Under physiologic conditions, this system is maintained by guanine nucleotide exchange factors, favoring the GDP-bound inactive form.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research